<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001584</url>
  </required_header>
  <id_info>
    <org_study_id>RGH-917-001</org_study_id>
    <nct_id>NCT02001584</nct_id>
  </id_info>
  <brief_title>A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gedeon Richter Plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gedeon Richter Plc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and
      obese (Part B), otherwise healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Safety and tolerability of co-administered baclofen and memantine via C-SSRS</measure>
    <time_frame>From Baseline until Follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of co-administered baclofen and memantine via Adverse Events</measure>
    <time_frame>From Baseline until Follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of co-administered baclofen and memantine via Vital Signs</measure>
    <time_frame>From Baseline until Follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of co-administered baclofen and memantine via ECG</measure>
    <time_frame>From Baseline until Follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of co-administered baclofen and memantine via Clinical Laboratory Tests</measure>
    <time_frame>From Baseline until Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via Cmax</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via Tmax</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via AUC</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via MRT</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via CL/F</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via T1/2</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of co-administered baclofen and memantine via CLR</measure>
    <time_frame>From Baseline until Day 32</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Healthy Volunteers;</condition>
  <condition>Obese, Otherwise Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, Otherwise Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Obese, Otherwise Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Obese, Otherwise Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Obese, Otherwise Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males or females aged 18 to 45 years inclusive;

          2. Subjects with body mass index:

             For Part A: ≥18 kg/m² and ≤25 kg/m²; For Part B: ≥33 kg/m² and ≤40 kg/m².

          3. Subjects with a total body weight of ≥50 kg (Part A and Part B);

          4. Subjects who are healthy as determined by the Investigator based on pre study medical
             history, physical examination, vital signs (blood pressure, pulse rate, respiratory
             rate and body temperature) and 12-lead ECG at screening and each admission;

          5. Subjects whose clinical laboratory test results are not clinically relevant and are
             acceptable to the Investigator at screening and each admission;

          6. Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and
             bilirubin ≤1.5 x upper limit of normal (ULN);

          7. Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis C
             antibody and human immunodeficiency virus (HIV) I and II tests at screening;

          8. Subjects who are negative for drugs of abuse and alcohol tests at screening and each
             admission;

          9. Subjects who are non-smokers or who have not smoked or used nicotine-containing
             products for at least 3 months prior to screening;

         10. Subjects with an estimated creatinine clearance ≥100 mL/minute for male subjects or

             ≥90 mL/minute for female subjects (Cockcroft-Gault method) at screening;

         11. Subjects who are able and willing to give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles Drug Research Unit at Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

